Aktienanalyse zu Lyell Immunopharma Inc (LYEL)LYELLyell Immunopharma Inc

Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Lyell Immunopharma is a good buy right now due to its current price of $10.88, which is significantly below the analyst price target of $44, indicating a potential upside of 304%. Additionally, the stock has shown a positive momentum with a 5-day change of +16.86% and a strong RSI of 69.98, suggesting bullish sentiment. The main risk is the high net loss reported for Q4 2025 of $140.7 million, which could impact investor confidence if not addressed effectively.